Oestrogen-replacement therapy and risk of ovarian cancer

Lancet

Volumn 358, Issue 9280, 2001, Pages 438-

  Weiss, Noel S ^a   Rossing, Mary Anne ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ETHINYLESTRADIOL; FOLLITROPIN; GESTAGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

BREAST CARCINOMA; CANCER MORTALITY; CANCER RISK; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; ESTROGEN THERAPY; FOLLOW UP; HUMAN; LONG TERM CARE; NOTE; OVARY CARCINOMA; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035845285     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)05669-0     Document Type: Note

References (9)

1. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women
2. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis
3. Endometrial cancer
4. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiologic studies of 52 705 women with breast cancer and 108 411 women without breast cancer
5. Effect of orally administered oestrogens on gonadotrophin levels in post-menopausal women
6. Serum gonadotropins and steroid hormones and the development of ovarian cancer
7. Ovarian cancer
8. Effect of progestin on the ovarian epithelium of macaques: Cancer prevention through apoptosis?
9. Biologic effect of progestins on the ovarian epithelium: Cancer prevention through apoptosis?